1.Research and prospect of tissue engineered blood vessels
Chinese Journal of Tissue Engineering Research 2007;0(33):-
The tissue engineering technology that developed in the 1980s brings a hope for the regeneration of human organs. It is feasible to construct by-pass vessels, which have no immune resistance but are capable of anticoagulation. At present, a huge number of researches have provided the necessary basis for the construction. However, there are still some difficulties on the points of induction and proliferation of endothelial cells, development of new materials for scaffold and co-culture of seed cells in scaffold. These difficulties have become the bottle neck of tissue engineered blood vessels. The tissue engineering vessels are nowadays absent in clinical practice. With the progress in researches of tissue engineering, it is strongly believed that human organs and tissues can be constructed using tissue engineering technology, thus satisfying the donors of organ transplantation.
3.The research on the efficacy and safety of recombinant human brain natriuretic peptide treating patients with de- compensated acute heart failure.
Xin XUE ; Shu-Mei LI ;
Chinese Journal of Practical Internal Medicine 2006;0(S2):-
Objective To compare the efficacy and safety of intravenous infusion of recombinant human brain natriuretic peptide(rhBNP)versus Sodium Nitroprusside on treating patients with decompensated acute heart failure.Discuss rhBNP 's effect on connective tissue of heart.Methods A total of 44 patients characterized of decompensated acute heart failure were enrolled in this study.The patients were randomLy allocated to rhBNP group who receive rhBNP(1.5?g/kg bolus intravenous injection followed by 0.0075?g/(kg?min)for 24 hours,n=23)and Sodium Nitroprusside group(10 ?g/ rain for 24 hours,n=21 ).Blood pressure,heart rate,dyspnea grade,24 hours fluid in-and-output and improvement in patient symptoms and signs were evaluated and adverse events were documented.Results Dyspnea and symptom im- provements were much more significant in rhBNP group compared to Sodium Nitroprusside group(P
5.Diagnosis and treatment of esthesioneuroblastoma
Guangxin LI ; Xin SHU ; Gong LI ; Miaomiao GOU
Journal of International Oncology 2014;41(5):338-341
Esthesioneuroblastoma is one of the most uncommon nasal malignancies which is characterized by low incidence and high misdiagnosis rate.The only prognosis factor is the metastasis on lymph node of neck.Its clinical symptoms are associated with tumor infiltrating extent.Pathological diagnosis is the “gold standard” on esthesioneuroblastoma,and the Kadish staging based on the image is the most important staging standard.The traditional operation therapy mode has been replaced by the combined method of operation and radiotherapy,with the adjunctive therapy of chemotherapy.
6.Misdiagnosis of cervical bronchogenic cyst with nodular goiter in a case.
Li-Juan LI ; Shu-Xin WEN ; Bin-Quan WANG
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2013;48(7):598-599
Bronchogenic Cyst
;
diagnosis
;
Diagnostic Errors
;
Goiter
;
Goiter, Nodular
;
diagnosis
;
Humans
;
Neck
8.Application of Diffusion Tensor Imaging in Stroke Rehabilitation (review)
Li-hua ZHANG ; Li-xin MI ; Shu-yan QIE
Chinese Journal of Rehabilitation Theory and Practice 2015;21(7):785-789
Diffusion tensor imaging is a non-invasive MRI technique which can identify changes of cerebral microstructure that CT and MRI is difficult to find, especially in the change of nerve fibers direction, which can be used for the researches of evaluation, recovery mechanism and prognosis of neurology. It has been applied in rehabilitation of motor, language and recognition of post-stroke patients.
9.Type and distribution of cells in goat temporomandibular joint discs and its significance in tissue engineering design
Weina SHU ; Hong KANG ; Weiping ZHANG ; Xin LI ; Guangjie BAO
Chinese Journal of Tissue Engineering Research 2009;13(46):9022-9026
BACKGROUND:There is no common cognition in the cell type in the temporomandibular joint(TMJ)discs,and names describing TMJ disc cells also vary a lot.OBJECTIVE:To characterize the type and the distribution of cells in the TMJ disc of goats DESIGN,TIME AND SETTING:A single sample observation was completed in Cettutar and Motecutar Biologicat Center and Electron Microscope Center of Lanzhou University from March to May in 2007.MATERlALS:TMJ discs were obtained from two one-month-old healthy goats that were slaughtered freshly.METHODS:Bilateral TMJ discs of goats were cut off completely and were divided into 6 parts by 3 cuts in the major axis direction (mediolaterally)and 2 cuts in the minor axis direction(anteroposteriorly).Then the marked samples were fixed in 10%neutral formalin Iiquid for 24 hours and embedded by paraffin.MAIN OUTCOME MEASURES:Hematoxylin and eosin staining were used to identify regional variation of cell type and cellnumbers.Toluidine blue staining and collagen type Ⅰimmunohistochemical assay were performed to test the distribution of collagens.Transmission etectren microscopy was used to observe the ultrastructure of cells of goat TMJ discs.RESULTS:TMJ discs were comprised of cells and collagen fibers distributing unevenly.Collagens were mostly type Ⅰ.Collagen fibers were wave or crimping and approximately parallel to each other.with cells scattered in their matrix.Fibroblast-like cells and chondrocyte-like cells were the main two types of cells existing,with the former predominating over the later in a ratio of 2.05:1 approximately.There were no significant regional differences in cell type and distribution statistically.Transmission electron microscopy denoted that fibroblast-iike cells have fairly larger fusiform or irregular nuclei with very few organelles,while the chondrocyte-like cells exhibited round or elliptical nuclei,well defined pericellular electron lucent zones,unconspicuous cytocysta and non-distinctive pseudopodia CONCLUSION:There are no significant differences in type,number and arrangement of cells in TMJ discs of one-month-old goats statistically,with Fibroblast-like cells predominating slightly over chondrocyte-like cells.
10.The efficacy of entecavir treatment on acute-on-chronic liver failure in patients with hepatitis B
Xin SHU ; Qihuan XU ; Ni CHEN ; Ka ZHANG ; Gang LI
Chinese Journal of Infectious Diseases 2009;27(5):281-286
Objective To evaluate the efficacy of entecavir treatment on hepatitis B patients with acute-on-chronic liver failure. Methods Eighty-four hepatitis B patients with acute-on-chronic liver failure were treated with entecavir 0.5 mg daily and Other routine drugs. Another 99 hepatitis B patients with acute-on-chronic liver failure were treated with only routine drugs as control. The survival, liver functions, hepatitis B virus (HBV) DNA level, prothrombin time (PT) were observed. The survival rates of patients with early, middle or late stage of liver failure were analyzed. The comparison of rates were done using chi-square test. The numeration data were compared by t test. The survival rates were compared using Kaplan-Meier method. Results Among patients with early stage of acute-on-chronic liver failure, the survival rate in treatment group was 63.3% (31/49), which was significantly higher than that in control group (39.7%, 23/58) (χ2=5.923, P=0.015). Among patients with middle stage of acute-on-chronic liver failure, the surviral rate in treatment group was 63.0% (17/27), which was significantly higher than that in control group (35.1%, 13/37) (χ2=4.854, P=0.028). Among patients with late stage of acute-on-chronic liver failure, four out of eight cases survived in treatment group, while one out of four cases survived in control group. In patients with serum total hilirubin (TBil) level > 342 μmol/L, the survival rate was 56.0% in treatment group, which was significantly higher than that in control group (26.8%) (χ2=9.351,P=0.002). At week 4 of the treatment, the HBV DNA reduction in treatment group was 3. 95 lg copy/mL, which was higher than that in control group (1.78 lg copy/mL) (t=5.847, P=0.001). Conclusions Entecavir treatment could improve the survival rate of hepatitis B patients with early or middle stage of acute-on-chronic liver failure. And the further study with larger population is needed in patients with late stage of liver failure. In addition, entecavir therapy could also improve the survival rate of patients with TBil >342 μmol/L.